Capital Research Global Investors Immunovant, Inc. Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Immunovant, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 976,237 shares of IMVT stock, worth $26.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
976,237
Previous 976,237
-0.0%
Holding current value
$26.9 Million
Previous $25.8 Million
4.21%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding IMVT
# of Institutions
211Shares Held
66.9MCall Options Held
2.3MPut Options Held
631K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.33MShares$91.6 Million0.06% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...